This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... decision has been made to specifically introduce and/or scale-up HPV virological testing for screening, which would be followed up with adequate management within the context of cervical cancer prevention
more
This guideline document lays out the indicators for monitoring the 2016 Political Declaration on ending AIDS. The Global AIDS Monitoring (GAM) process has been often referenced as a benchmark for successful international accountability mechanisms.
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ...Report package.
Available in different languages: http://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en
more
Version: 14 March 2019; A one-page reference guide to all the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
The previous edition of the drugs chart is also available to download in Russian.
Amphetamine-type stimulants, new psychoactive substances
-4-
World Drug Report 2017
Accessed: 14.03.2019
Opiates, cocaine, cannabis
World Drug Report 2017
-3-
Accessed: 14.03.2019
This analytical report reviews and discusses the potential role and influence of political commitment in implementing endorsements and conducting policy in the field of tuberculosis (TB) prevention and care. It promotes discussion by comparing and analysing the extent to which selected international... commitments, set out in declarations and other committal documents between 2000 and 2018, may have translated into sustainable action. This reflection is relevant and timely, as the United Nations high-level meeting (UNHLM) on TB recently took place, offering countries the opportunity to take stock of progress made, refocus efforts, and step up global commitments to achieve the United Nations Sustainable Development Goal of eliminating TB by 2030
more
Guidance
Indicators for monitoring the 2016 Political Declaration on Ending AIDS
UNAIDS Joint United Nations Programme on HIV/AIDS
Tema 8.22 da agenda provisória
Washington, D.C., EUA, 23 a 27 de setembro de 2018
CD56/INF/22 31 de agosto de 2018
Original: inglês/espanhol
Washington, D.C., EUA, del 23 al 27 de septiembre del 2018
Punto 8.22 del orden del día provisional
CD56/INF/22 31 de agosto del 2018
Original: inglés/español
UNAIDS 2018, Guidance
Indicators for monitoring the
2016 Political Declaration on Ending AIDS
Meeting report, 25-26 September 2017 Copenhagen, Denmark
The Millennium Development Goals (MDGs) showed
that global commitment and collective action
could significantly reduce the disease burdens of
three deadly communicable diseases: HIV/AIDS,
tuberculosis (TB) and malaria. The MDGs helped
focus efforts on these three deadly diseases
and leveraged ...disease-specific programmes and
financing, thus achieving significant progress.
more
Indicators for monitoring the 2016 United Nations Political Declaration on Ending AIDS
UNAIDS supports countries to collect information on their national HIV responses through the Global AIDS Monitoring (GAM) framework—an annual collection of 72 indicators on the response to HIV in a country.... These data form part of the data set used to report back to the General Assembly.
Different from the HIV epidemiological estimates that countries produce for data on the state of the epidemic in a country—that is, data for making estimates on the number of people living with HIV, AIDS-related deaths, etc.—GAM collects information on HIV programmes, including the number of people living with HIV who know their HIV status and people on HIV treatment, and on stigma and discrimination. A full list of the indicators is given in the GAM guidelines.
more
3rd Edition – July 2017
www.msfaccess.org